A new study suggests that simple, targeted strategies, from using telehealth to standardizing patient referrals, could help more people with Parkinson’s disease get the specialized care they urgently need. With U.S. cases expected to double by 2040, researchers warn that existing healthcare inequities will worsen without immediate action. “Research…
People with metabolic syndrome, a cluster of metabolism-related abnormalities — like a larger waist circumference, high blood sugar, and abnormal blood levels of fatty molecules — may have a higher risk of Parkinson’s disease, according to the findings of a new study by an international team of researchers. Having…
Parkinson’s disease patients who receive donor-derived brain stem cell therapy may be able to avoid potent immunosuppressant drugs without showing signs of rejection, a study in Japan suggested. The Phase 1/2 trial (jRCT2090220384) tested transplants of dopamine-producing precursor cells made from induced pluripotent stem cells (iPSCs) — stem…
An oral anti-inflammatory therapy for Parkinson’s disease developed using artificial intelligence (AI) may be nearing clinical trials. Insilico Medicine said it plans to seek clearance later this year from the U.S. Food and Drug Administration (FDA) to advance the therapy, ISM8969, into human trials. The company said its…
OM1 has expanded a real-world dataset of people with neurological conditions, including Parkinson’s disease, adding health records and clinical notes for 500,000 more people. “Expanding our neurology network to more than 3 million patients represents a pivotal milestone in enabling better outcomes for neurology patients,” Carl Marci, MD,…
Seal Rock Therapeutics has joined a Michael J. Fox Foundation (MJFF) initiative to develop therapies targeted at the LRRK2 gene for the treatment of Parkinson’s disease. The program, LRRK2 Investigative Therapeutics Exchange (LITE), brings together academic and industry collaborators to support preclinical and clinical development aimed…
The Parkinson’s Foundation has announced that it will provide more than $4.3 million toward 44 research grants that seek to advance understanding of Parkinson’s disease and support efforts toward a cure. “The Parkinson’s Foundation is excited to support these brilliant scientists and see how they are approaching Parkinson’s…
Most people with Parkinson’s disease who’d experienced recurring falls found a personalized, home-based fall prevention program in Australia helpful for improving their safety and confidence. That’s according to a new assessment of the six-month program, dubbed Integrate, which was shown to reduce fall rates by nearly half among participants…
Continuous exposure to low-oxygen air halted neurodegeneration and eased or reversed motor symptoms in a mouse model of Parkinson’s disease, a study reports. “The results raise the possibility of an entirely new paradigm for addressing Parkinson’s,” Fumito Ichinose, MD, PhD, senior coauthor of the study, said in a…
ENERGI-F705PD, a potential disease-modifying therapy for Parkinson’s disease, was found to be safe and well tolerated in a Phase 1 clinical trial involving healthy volunteers, according to developer Energenesis Biomedical. Unlike currently available treatments, ENERGI-F705PD aims to address the causes of Parkinson’s and not just its symptoms.
Get regular updates to your inbox.
